New Research Pulls Back the Curtain on Enterprise Content Marketing in 2019

The Content Advisory | February 07, 2019

With thousands of employees, working across multiple brands, products lines, offices and silos, enterprise marketers face unique content marketing challenges, yet many are scoring wins year after year. That’s according to the findings in the Content Marketing Institute’s new research report, Enterprise Content Marketing 2019: Benchmarks, Budgets, and Trends—North America, sponsored by Seismic. The report looks at how enterprise marketers have changed their content marketing practices over the last year. 68% of enterprise respondents said their organization was much more/somewhat more successful with content marketing compared with one year ago. 43% of respondents rated their organization’s content marketing maturity as sophisticated/mature. 61% reported their organization is extremely/very committed to content marketing. 71% say content marketing technology is providing better insight into how their content is performing. 74% cited “coordinating content marketing efforts among multiple departments and brands” as the top unique content marketing challenge they face.

Spotlight

Infographic from MBA Healthcare Management provides a deep look into how the United States healthcare system is broken falling short of other industrial countries.


Other News
FUTURE OF HEALTHCARE

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions. “We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.” Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology. “The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago. About Medicago Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group.

Read More

HEALTH TECHNOLOGY

Titan Medical Announces Purchase Order from Medtronic

Titan Medical Inc. | May 04, 2022

Titan Medical Inc. a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery announced receipt of a $2.6 million purchase order from Medtronic plc a global leader in healthcare technology. The order covers the purchase of instruments and cameras that will be used in preclinical activities and the evaluation of Titan Medical as a potential manufacturing and supply partner for Medtronic. “Medtronic has been a great partner for Titan since 2020 and we’re excited about this opportunity to further our work together. Our manufacturing team and capabilities continue to expand at our operations in Chapel Hill. With this order, we will produce instruments and cameras for Medtronic’s evaluation and testing in addition to producing instruments and cameras for our own single-access RAS platform, Enos.” Paul Cataford, Interim President and CEO of Titan For clarity, these agreements are between Medtronic and Titan Medical Inc. Titan Medical is not affiliated with Titan Spine, which Medtronic acquired in 2019. About Titan Medical Titan Medical Inc. a medical device company headquartered in Toronto, Ontario, with operations in Chapel Hill, North Carolina, is focused on enhancing robotic-assisted surgery (RAS) using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand. The Enos system includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. Titan intends to initially pursue gynecologic surgical indications with the Enos

Read More

HEALTH TECHNOLOGY

Valtruis Brings Advanced Healthcare Data Analytics Capabilities Into Its Portfolio With Ursa Health Partnership

Ursa Health and Valtruis | June 28, 2022

Valtruis, a WCAS company, has entered a strategic partnership with Ursa Health, a healthcare data analytics company that brings a paradigm-breaking approach to how healthcare organizations use their data to learn, make decisions, and innovate Valtruis portfolio companies Cricket Health and Wayspring are already experiencing quantifiable advances in their data analysis and management capabilities through both the Ursa Studio no-code analytics development platform and the unusually productive training, support, and consultative relationships they have formed with Ursa Health’s team of healthcare IT and data analytics experts. “Building on the investments made in our first year – with Cricket Health, Wayspring, U.S. Medical Management (USMM) and Oncology Care Partners – we are moving quickly and strategically to realize our foundational commitment,” said Valtruis Managing Director Karey Witty. “That commitment is to accelerate the adoption of value-based care through investments in and collaboration with companies and entrepreneurs that share the vision, talent, and innovative strategies to make value-based care a reality. Ursa Health is one of those companies.” “We bring scalable innovation to healthcare. Companies driving toward meaningful strategic innovation need their data to provide richer, more nuanced answers than healthcare as an industry has historically delivered – and they need these insights at the speed of business. Ursa Studio is a technology that unlocks a fresh approach to developing trusted information. On the technical level, the platform shifts IT team time from the labor of debugging code and managing data plumbing, opening up their capacity to answer additional business questions. On the human level, the platform enables rapid iteration and collaboration between the producers and consumers of analytics, bringing teams to a successful endpoint more quickly. As a result, organizations gain the self-service capacity to fill their information gaps and guide their innovations more efficiently and effectively.” Ursa Health CEO and Co-Founder Robin Clarke, MD Early-phase successes from Valtruis’ partner companies attest to the value, intelligence, and flexibility of the Ursa Health technology and analytics approach. Adam Dunning, Chief Information and Analytics Officer at Wayspring, stated: “We needed a solution to fast-track the development of our SUD Home offering. Working with Ursa Studio, allowed us to accelerate the building of foundational data analytics structures. Our clients and staff will see notable returns as we continue to master the technology offering developed by Ursa Health.” About Valtruis Valtruis, a WCAS company, provides a unique platform that invests in and partners with disruptive leaders whose mission is to align, and transform healthcare through what is truly value-based care. Founded on a commitment to accelerate meaningful change, Valtruis brings the functional expertise, access to capital, and an expansive network that advance our partners’ evolution from early-stage development to industry-leading enterprises. Together, Valtruis and its partner companies will break through the systemic barriers in the healthcare industry to reduce costs, expand access, increase quality, and radically improve the patient experience. About Ursa Health Ursa Health is transforming analytics so innovators can transform healthcare. Our analytics development platform, Ursa Studio, combines no-code technology with healthcare-specific content, enabling health plans, providers, digital health companies, and others to take a Buy Your Build™ approach to their analytics infrastructure. With the structured adaptability of Ursa Studio, organizations can make full use of their rich data resources to accelerate growth.

Read More

HEALTH TECHNOLOGY

athenahealth Expands Mobile EHR Voice Capabilities for Healthcare Providers

athenahealth, Inc. | June 29, 2022

athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, announced the release of athenaOne® Voice Assistant Powered by Nuance®, a mobile-embedded, voice-driven digital companion that streamlines information retrieval and enables hands-free completion of meaningful clinical tasks for healthcare providers using athenahealth’s electronic health records (EHR) solution. Leveraging the power of their voice and iOS-based mobile device, clinicians can spend less time on the computer and more time interacting with patients. Voice Assistant is a natural command-based, virtual assistant developed and built by athenahealth and powered by Nuance's Dragon Medical technology. Voice Assistant is available for use with the award-winning athenaOne mobile app and athenaOne® Dictation Powered by Nuance®, which allows clinicians to dictate patient documentation naturally and accurately. Together, athenahealth’s voice-enabled solutions help clinicians improve documentation accuracy, save time, and provide a better patient experience. According to a recent survey by athenahealth, 92% of physicians surveyed report one or more issues cause them to feel burned out on a regular basis with the leading cause of regular burnout being excessive documentation requirements. However, numerous clinicians using Voice Assistant have experienced significant documentation time savings, thus allowing them to reallocate their time to other high-priority tasks. “I started using Voice Assistant because I’m curious about tech and AI, and I wanted to see if it would help me be more productive. Because I can so easily document anywhere, anytime, I’ve found it to be very useful and convenient, and it helps me make better use of my time. I wouldn’t want to work without it now.” Dr. Terence M. Grogan, DO, FAAFP, Grogan Family Medicine Using simple, intuitive voice commands, clinicians using Voice Assistant can document exams, create draft orders, retrieve clinical information, and review their schedule to accelerate tasks and save valuable time. As an AI-backed technology, Voice Assistant will become even smarter and more efficient with widespread use, and athenahealth will continue to expand the number of available commands and introduce new use cases. “We are delighted to expand our provider mobile app capabilities with Voice Assistant as we continue to transform the provider and patient experience,” said Paul Brient, chief product officer for athenahealth. “Clinicians should be able to experience technology at work just like they do in their everyday lives, and Voice Assistant brings us one step closer to that.” Brient added that with provider burnout and patient expectations increasing simultaneously, athenahealth is focused on accelerating product innovation, using tools like AI to help solve some of healthcare's biggest challenges. “As our data show, administrative requirements are taking too much time and attention away from providers, and it’s the responsibility of all EHR companies to decrease that burden so providers can spend more face time with patients,” he said. About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all.

Read More